Interpace Biosciences announces Q4 earnings, stock price flat

Parsippany, New Jersey — Interpace Biosciences, Inc. (OTCQX:IDXG) reported Monday that its fourth-quarter adjusted earnings per share were $0.82, with revenue of $9.2 million.

Revenue from the company’s thyroid business rose 14% year over year in the quarter, while total revenue fell 26% to $12.4 million from the same period last year, reflecting the company’s discontinuation of its PancraGEN product line in May 2025.

For full fiscal year 2025, total revenue totaled $38.7 million, down 18% from $46.9 million in 2024. However, revenue from the thyroid segment increased 21% year over year for the full year.

The company reported that revenue from continuing operations was $22.8 million for the quarter and $25.0 million for the year, benefiting from a one-time, non-cash tax-related accounting adjustment related to the release of a valuation allowance for deferred tax items.

Chief Financial Officer Chris McCarthy said: “The company delivered strong thyroid business performance in the fourth quarter, bringing a successful close to our year of transformation. We completed our transition to a pure-play thyroid diagnostic testing company. In the fourth quarter of 2025, thyroid revenue grew 14% year over year, and full-year 2025 rose 21% year over year, while thyroid test volumes increased 11% and 13%, respectively.”

The company reported adjusted EBITDA of $1.7 million for the quarter, compared with $2.2 million in the prior-year period. Adjusted EBITDA for the full year was $5.4 million, compared with $8.7 million in 2024.

In the fourth quarter, Interpace fully repaid its debt, and cash availability increased by $4.3 million year over year. The company’s 2026 outlook provided indicates that thyroid business revenue is expected to grow by approximately 16% year over year.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.